Invion Ltd (IVX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Invion Ltd (IVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7998
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company’s pipeline products include INV102 nadolol, a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium for the treatment of chronic inflammatory airway diseases; INV103 ala-Cpn10, a naturally occuring human protein for the treatment of chronic inflammation; and INV104 zafirlukast, a leukotriene receptor antagonist for the prevention of asthma attacks. Invion also conducts clinical development programs for developing zafirlukast as a novel non-steroidal, anti-inflammatory treatment to prevent asthma attacks. The company has operations in Melbourne, Australia; and Delaware, the US. Invion is headquartered in Melbourne, Victoria, Australia.

Invion Ltd (IVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Invion Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Invion Enters into R&D Agreement with Hudson Institute of Medical 10
Invion Enters into Development and Licensing Agreement with Hovione 11
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 12
Licensing Agreements 13
Chronic Airway Therapeutics to Receive Respiratory Assets from Invion 13
Invion Enters into Licensing Agreement with Cho Group 14
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 15
Equity Offering 17
Invion Raises USD19.46 Million in Rights Offering of Shares 17
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 18
Invion Raises USD0.4 Million in Private Placement of Shares 19
Invion to Raise USD15 Million in Private Placement of Shares 20
Invion Completes Rights Offering Of Shares For USD0.8 Million 21
Invion Completes Private Placement Of Shares For US$4.5 Million 23
Invion Completes Private Placement Of Shares For US$1.9 Million 24
Invion Completes Rights Offering Of Shares For US$1 Million 25
Acquisition 27
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 27
Invion Ltd – Key Competitors 29
Invion Ltd – Key Employees 30
Invion Ltd – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 28, 2018: Invion – Highlights of appendix 4E and full year financial results 32
Corporate Communications 34
Mar 22, 2018: Change to Invion Board of Directors 34
Mar 21, 2018: Leading Ovarian Cancer Expert Dr Andrew Stephens Appointed to Invion’s Advisory Board 35
Dec 01, 2017: Invion Appoints Mr Thian Chew As Director And Chairman 36
Government and Public Interest 37
Jul 05, 2018: Photosoft Efficiently Destroys Ovarian Cancer Cells In Vitro 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Invion Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Invion Enters into R&D Agreement with Hudson Institute of Medical 10
Invion Enters into Development and Licensing Agreement with Hovione 11
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 12
Chronic Airway Therapeutics to Receive Respiratory Assets from Invion 13
Invion Enters into Licensing Agreement with Cho Group 14
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 15
Invion Raises USD19.46 Million in Rights Offering of Shares 17
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 18
Invion Raises USD0.4 Million in Private Placement of Shares 19
Invion to Raise USD15 Million in Private Placement of Shares 20
Invion Completes Rights Offering Of Shares For USD0.8 Million 21
Invion Completes Private Placement Of Shares For US$4.5 Million 23
Invion Completes Private Placement Of Shares For US$1.9 Million 24
Invion Completes Rights Offering Of Shares For US$1 Million 25
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 27
Invion Ltd, Key Competitors 29
Invion Ltd, Key Employees 30

List of Figures
Invion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Invion Ltd (IVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析
    Summary Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops therapies for kidney transplantation based on its proprietary MeltDose platform. MeltDose is a drug delivery technology, used to enhance oral bioavailability and control release of a drug. The company …
  • Grain Processing Corp:企業の戦略的SWOT分析
    Grain Processing Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cancer Genetics Inc (CGIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic info …
  • Lamar Advertising Company (LAMR):企業の財務・戦略的SWOT分析
    Lamar Advertising Company (LAMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Gavilon Agriculture Holdings Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Gavilon Agriculture Holdings Co (Gavilon) is a merchandising service provider that offers essential agricultural commodities and services. The company’s products include grains and oilseeds, feed ingredients, fertilizers, and food ingredients, among others. Its feed ingredients comprise anim …
  • Point Resources AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Point Resources AS (Point Resources) ,is engaged in developing, exploring and production of petroleum products. It explores and produces crude oil, gas and natural gas liquids (NGLs) through Ringhorne, Balder and Jotun fields. Point Resources also offers seismic surveys and drilling services …
  • Anteo Diagnostics Ltd (ADO):企業の財務・戦略的SWOT分析
    Anteo Diagnostics Ltd (ADO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hopewell Holdings Ltd (54):企業の財務・戦略的SWOT分析
    Hopewell Holdings Ltd (54) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • The Empire District Electric Co:電力:M&Aディール及び事業提携情報
    Summary The Empire District Electric Co (EDE), a subsidiary of Liberty Utilities Co, is a regulated utility that provides electricity, natural gas, and water services. The company generates, procures, transmits, distributes, and sells electricity. It generates electricity from natural gas, coal, and …
  • Ingenico SA (ING):企業の財務・戦略的SWOT分析
    Ingenico SA (ING) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Talisman Mining Ltd (TLM):企業の財務・戦略的SWOT分析
    Summary Talisman Mining Ltd (Talisman Mining) is a mining and mineral exploration and development company. The company explores for copper-gold, base metal, and gold deposits. Its projects portfolio includes Springfield project, Sinclair Nickel Project, Milgun Project, Halloween and Halloween West J …
  • Revenio Group Oyj (REG1V):企業の財務・戦略的SWOT分析
    Revenio Group Oyj (REG1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • GfK SE:企業のM&A・事業提携・投資動向
    GfK SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GfK SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Naftna industrija Srbije ad (NIIS):企業の財務・戦略的SWOT分析
    Naftna industrija Srbije ad (NIIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • WSI Industries, Inc.:企業の戦略・SWOT・財務情報
    WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Swallowfield PLC:企業の戦略・SWOT・財務情報
    Swallowfield PLC - Strategy, SWOT and Corporate Finance Report Summary Swallowfield PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bell Food Group Ltd:戦略・SWOT・企業財務分析
    Bell Food Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Bell Food Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SenesTech Inc (SNES):企業の財務・戦略的SWOT分析
    SenesTech Inc (SNES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Aozora Bank Ltd:企業の戦略・SWOT・財務情報
    Aozora Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Aozora Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • 01 Communique (ONE):企業の財務・戦略的SWOT分析
    Summary 01 Communique (Communique) is a technology company that develops and delivers integrated communication software and services. The company's products include I'm InTouch meeting, I'm InTouch, I'm OnCall and Communicate!. Its I'm InTouch provides a secure and easy to use PC remote access softw …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆